{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:23:54Z","timestamp":1790187834727,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","award":["Pilot Grant"],"award-info":[{"award-number":["Pilot Grant"]}],"id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["R01CE003143"],"award-info":[{"award-number":["R01CE003143"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The majority of individuals with opioid use disorder (OUD) face access barriers to evidence-based treatment, and the COVID-19 pandemic has exacerbated the United States (US) opioid overdose crisis. However, the pandemic has also ushered in rapid transitions to telehealth in the USA, including for substance use disorder treatment with buprenorphine. These changes have the potential to mitigate barriers to care or to exacerbate pre-existing treatment inequities. The objective of this study was to qualitatively explore Philadelphia-based low-barrier, harm-reduction oriented, opioid use disorder (OUD) treatment provider perspectives about and experiences with telehealth during the COVID-19 pandemic, and to assess their desire to offer telehealth to patients at their programs in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We interviewed 22 OUD treatment prescribers and staff working outpatient programs offering OUD treatment with buprenorphine in Philadelphia during July and August 2020. All participants worked at low-barrier treatment programs that provide buprenorphine using a harm reduction-oriented approach and without mandating counseling or other requirements as a condition of treatment. We analyzed the data using thematic content analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis yielded three themes: 1\/\n                      <jats:italic>Easier access for some<\/jats:italic>\n                      : telehealth facilitates care for many patients who have difficulty attending in-person appointments due to logistical and psychological barriers; 2\/\n                      <jats:italic>A layered digital divide<\/jats:italic>\n                      : engagement with telehealth can be seriously limited by patients\u2019 access to and comfort with technology; and 3\/\n                      <jats:italic>Clinician control:<\/jats:italic>\n                      despite some clinic staff beliefs that patients should have the freedom to choose their treatment modality, patients\u2019 access to treatment via telehealth may hinge on clinician perceptions of patient \u201cstability\u201d rather than patient preferences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Telehealth may address many access issues, however, barriers to implementation remain, including patient ability and desire to attend healthcare appointments virtually. In addition, the potential for telehealth models to extend OUD care to patients currently underserved by in-person models may partially depend on clinician comfort treating patients deemed \u201cunstable\u201d via this modality. The ability of telehealth to expand access to OUD care for individuals who have previously struggled to engage with in-person care will likely be limited if these patients are not given the opportunity to receive treatment via telehealth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00572-7","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:32:03Z","timestamp":1638279123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-9562","authenticated-orcid":false,"given":"Shoshana V.","family":"Aronowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Engel-Rebitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Oyekanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"572_CR1","unstructured":"CDC\/NCHS. National vital statistics system, mortality. Atlanta: US Department of Health and Human Services: CDC WONDER; 2018. Available from https:\/\/wonder.cdc.gov."},{"key":"572_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev-publhealth-082619-104231","volume":"42","author":"S Harper","year":"2021","unstructured":"Harper S, Riddell CA, King NB. Declining life expectancy in the United States: missing the trees for the forest. Annu Rev Public Health Annu Rev. 2021;42:381\u2013403.","journal-title":"Annu Rev Public Health Annu Rev"},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"1","author":"L-T Wu","year":"2016","unstructured":"Wu L-T, Zhu H, Swartz Marvin S. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;1:117\u201327.","journal-title":"Drug Alcohol Depend"},{"key":"572_CR4","first-page":"CD011117","volume":"5","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5:CD011117.","journal-title":"Cochrane Database Syst Rev"},{"key":"572_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19:1\u20138.","journal-title":"Curr Psychiatry Rep"},{"key":"572_CR6","doi-asserted-by":"publisher","first-page":"102821","DOI":"10.1016\/j.drugpo.2020.102821","volume":"83","author":"TS Bartholomew","year":"2020","unstructured":"Bartholomew TS, Nakamura N, Metsch LR, Tookes HE. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020;83:102821.","journal-title":"Int J Drug Policy"},{"key":"572_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/M20-1212","volume":"173","author":"ND Volkow","year":"2020","unstructured":"Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173:61\u20132.","journal-title":"Ann Intern Med"},{"key":"572_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1001\/jamapsychiatry.2020.4218","volume":"78","author":"J Friedman","year":"2020","unstructured":"Friedman J, Beletsky L, Schriger DL. Overdose-related cardiac arrests observed by emergency medical services during the US COVID-19 epidemic. JAMA Psychiat. 2020;78:562.","journal-title":"JAMA Psychiat"},{"key":"572_CR9","doi-asserted-by":"publisher","first-page":"e2034878","DOI":"10.1001\/jamanetworkopen.2020.34878","volume":"4","author":"UG Khatri","year":"2021","unstructured":"Khatri UG, Pizzicato LN, Viner K, Bobyock E, Sun M, Meisel ZF, et al. Racial\/ethnic disparities in unintentional fatal and nonfatal emergency medical services\u2014attended opioidoverdoses during theCOVID-19 pandemic in Philadelphia. JAMA Netw Open. 2021;4:e2034878.","journal-title":"JAMA Netw Open"},{"key":"572_CR10","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.drugpo.2020.102905","volume":"93","author":"CS Davis","year":"2020","unstructured":"Davis CS, Samuels EA. Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. Int J Drug Policy. 2020;93:102905.","journal-title":"Int J Drug Policy"},{"key":"572_CR11","unstructured":"U.S. Department of Justice Drug Enforcement Administration. Use of telemedicine while providing medication assisted treatment (MAT). Available from https:\/\/www.hhs.gov\/opioids\/sites\/default\/files\/2018-09\/hhs-telemedicine-dea-final-508compliant.pdf."},{"key":"572_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.17730\/1938-3525-79.4.292","volume":"79","author":"ER Eaves","year":"2020","unstructured":"Eaves ER, Trotter RT, Baldwin JA. Another silver lining?: Anthropological perspectives on the promise and practice of relaxed restrictions for telemedicine and medication-assisted treatment in the context of COVID-19. Hum Organ. 2020;79:292\u2013303.","journal-title":"Hum Organ"},{"key":"572_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1057\/biosoc.2015.46","volume":"12","author":"J Netherland","year":"2017","unstructured":"Netherland J, Hansen H. White opioids: pharmaceutical race and the war on drugs that wasn\u2019t. BioSocieties. 2017;12:217\u201338.","journal-title":"BioSocieties"},{"key":"572_CR14","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11013-016-9496-5","volume":"40","author":"J Netherland","year":"2016","unstructured":"Netherland J, Hansen HB. The war on drugs that wasn\u2019t: wasted whiteness, \u201cdirty doctors\u201d, and race in media coverage of prescription opioid misuse. Cult Med Psychiatry. 2016;40:664\u201386.","journal-title":"Cult Med Psychiatry"},{"key":"572_CR15","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.jsat.2021.108444","volume":"131","author":"BM Buchheit","year":"2021","unstructured":"Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J. Low-barrier buprenorphine during the COVID-19 pandemic: a rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat. 2021;131:108444.","journal-title":"J Subst Abuse Treat"},{"key":"572_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000809","author":"B Tofighi","year":"2021","unstructured":"Tofighi B, McNeely J, Walzer D, Fansiwala K, Demner A, Chaudhury CS, Subudhi I, Schatz D, Reed T, Krawczyk N. A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system's initiative to expand treatment access during the COVID-19 pandemic. J Addict Med. 2021. https:\/\/doi.org\/10.1097\/ADM.0000000000000809.","journal-title":"J Addict Med."},{"key":"572_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-020-00438-4","volume":"17","author":"M Castillo","year":"2020","unstructured":"Castillo M, Conte B, Hinkes S, Mathew M, Na CJ, Norindr A, et al. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic. Harm Reduct J. 2020;17:88.","journal-title":"Harm Reduct J"},{"key":"572_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14:95\u20138.","journal-title":"J Addict Med"},{"key":"572_CR19","unstructured":"Philadelphia Department of Public Health. Opioid overdoses. 2019 Feb. Available from https:\/\/hip.phila.gov\/EmergentHealthTopics\/Opioids."},{"key":"572_CR20","unstructured":"Philadelphia Department of Public Health. The impact of COVID-19 on unintentional drug overdoses in Philadelphia. 2020 Aug. Available from https:\/\/medium.com\/@PHLPublicHealth\/the-impact-of-covid-19-on-unintentional-drug-overdoses-in-philadelphia-4cde184d2679."},{"key":"572_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/08897077.2018.1443541","volume":"39","author":"MA Bachhuber","year":"2018","unstructured":"Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abuse. 2018;39:167\u201372.","journal-title":"Subst Abuse"},{"key":"572_CR22","doi-asserted-by":"publisher","first-page":"108342","DOI":"10.1016\/j.jsat.2021.108342","volume":"127","author":"DT O\u2019Gurek","year":"2021","unstructured":"O\u2019Gurek DT, Jatres J, Gibbs J, Latham I, Udegbe B, Reeves K. Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting. J Subst Abuse Treat. 2021;127:108342.","journal-title":"J Subst Abuse Treat"},{"key":"572_CR23","doi-asserted-by":"publisher","DOI":"10.1377\/hblog20190920.981503","author":"A McBournie","year":"2019","unstructured":"McBournie A, Duncan A, Connolly E, Rising J. Methadone barriers persist, despite decades of evidence. Health Aff Blog. 2019. https:\/\/doi.org\/10.1377\/hblog20190920.981503.","journal-title":"Health Aff Blog."},{"key":"572_CR24","doi-asserted-by":"publisher","first-page":"e2118223","DOI":"10.1001\/jamanetworkopen.2021.18223","volume":"4","author":"PJ Joudrey","year":"2021","unstructured":"Joudrey PJ, Adams ZM, Bach P, Van Buren S, Chaiton JA, Ehrenfeld L, et al. Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada. JAMA Netw Open. 2021;4:e2118223.","journal-title":"JAMA Netw Open"},{"key":"572_CR25","unstructured":"Centers for Disease Control. The social-ecological model: a framework for prevention. 2021. Available from https:\/\/www.cdc.gov\/violenceprevention\/about\/social-ecologicalmodel.html."},{"key":"572_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/0890334419830990","volume":"35","author":"JE Dodgson","year":"2019","unstructured":"Dodgson JE. Reflexivity in qualitative research. J Hum Lact. 2019;35:220\u20132.","journal-title":"J Hum Lact"},{"key":"572_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1728466","author":"N Brunet","year":"2020","unstructured":"Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus. 2020. https:\/\/doi.org\/10.1080\/08897077.2020.1728466.","journal-title":"Subst Abus."},{"key":"572_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamainternmed.2018.1314","volume":"178","author":"N Lurie","year":"2018","unstructured":"Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA Intern Med. 2018;178:745\u20136.","journal-title":"JAMA Intern Med"},{"key":"572_CR29","doi-asserted-by":"publisher","first-page":"103622","DOI":"10.1016\/j.jbi.2020.103622","volume":"112","author":"AH Talal","year":"2020","unstructured":"Talal AH, Sofikitou EM, Jaanim\u00e4gi U, Zeremski M, Tobin JN, Markatou M. A framework for patient-centered telemedicine: application and lessons learned from vulnerable populations. J Biomed Inform. 2020;112:103622.","journal-title":"J Biomed Inform"},{"key":"572_CR30","doi-asserted-by":"publisher","unstructured":"Khatri U, Davis CS, Krawczyk N, Lynch M, Berk J, Samuels EA. These key telehealth policy changes would improve buprenorphine access while advancing health equity. Health Aff Blog. 2021; Available from https:\/\/www.healthaffairs.org\/do\/https:\/\/doi.org\/10.1377\/hblog20200910.498716\/full\/.","DOI":"10.1377\/hblog20200910.498716\/full"},{"key":"572_CR31","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.jaad.2020.07.043","volume":"83","author":"M Bakhtiar","year":"2020","unstructured":"Bakhtiar M, Elbuluk N, Lipoff JB. The digital divide: how COVID-19\u2019s telemedicine expansion could exacerbate disparities. J Am Acad Dermatol. 2020;83:e345\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"572_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.120.048185","volume":"142","author":"LA Eberly","year":"2020","unstructured":"Eberly LA, Khatana SAM, Nathan AS, Snider C, Julien HM, Deleener ME, et al. Telemedicine outpatient cardiovascular care during the COVID-19 pandemic. Circulation. 2020;142:510\u20132.","journal-title":"Circulation"},{"key":"572_CR33","doi-asserted-by":"publisher","first-page":"1631583","DOI":"10.1080\/23311908.2019.1631583","volume":"6","author":"F Calvo","year":"2019","unstructured":"Calvo F, Carbonell X, Johnsen S. Information and communication technologies, e-Health and homelessness: a bibliometric review. Cogent Psychol. 2019;6:1631583.","journal-title":"Cogent Psychol."},{"key":"572_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(20)31033-3","volume":"396","author":"L Platt","year":"2020","unstructured":"Platt L, Elmes J, Stevenson L, Holt V, Rolles S, Stuart R. Sex workers must not be forgotten in the COVID-19 response. Lancet. 2020;396:9\u201311.","journal-title":"Lancet"},{"key":"572_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/0020872820962202","volume":"63","author":"E Lam","year":"2020","unstructured":"Lam E. Pandemic sex workers\u2019 resilience: COVID-19 crisis met with rapid responses by sex worker communities. Int Soc Work. 2020;63:777\u201381.","journal-title":"Int Soc Work"},{"key":"572_CR36","doi-asserted-by":"publisher","first-page":"102880","DOI":"10.1016\/j.drugpo.2020.102880","volume":"83","author":"M Tyndall","year":"2020","unstructured":"Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020;83:102880.","journal-title":"Int J Drug Policy"},{"key":"572_CR37","doi-asserted-by":"publisher","first-page":"108276","DOI":"10.1016\/j.jsat.2021.108276","volume":"123","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;123:108276.","journal-title":"J Subst Abuse Treat"},{"key":"572_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108552","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Thorn EL, Lutz R, Joudrey PJ. Changes in methadone take-home dosing before and after COVID-19. J Subst Abuse Treat. 2021. https:\/\/doi.org\/10.1016\/j.jsat.2021.108552.","journal-title":"J Subst Abuse Treat."},{"key":"572_CR39","doi-asserted-by":"publisher","unstructured":"Levander XA, Pytell JD, Stoller KB, Todd Korthuis P, Chander G. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership, Subst Abuse. https:\/\/doi.org\/10.1080\/08897077.2021.1986768.","DOI":"10.1080\/08897077.2021.1986768"},{"key":"572_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108258","volume":"123","author":"UG Khatri","year":"2021","unstructured":"Khatri UG, Aronowitz SV. Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment. J Subst Abuse Treat. 2021;123:108258. https:\/\/doi.org\/10.1016\/j.jsat.2020.108258.","journal-title":"J Subst Abuse Treat."},{"key":"572_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pain.2012.07.034","volume":"154","author":"LRM Hausmann","year":"2013","unstructured":"Hausmann LRM, Gao S, Lee ES, Kwoh K. Racial disparities in the monitoring of patients on chronic opioid therapy. Pain. 2013;154:46\u201352.","journal-title":"Pain"},{"key":"572_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-107030","author":"AS Beck","year":"2021","unstructured":"Beck AS, Svirsky L, Howard D. \u2018First do no harm\u2019: physician discretion, racial disparities and opioid treatment agreements. J Med Ethics. 2021. https:\/\/doi.org\/10.1136\/medethics-2020-107030.","journal-title":"J Med Ethics"},{"key":"572_CR43","doi-asserted-by":"crossref","unstructured":"Winchester M-L, Solverson EB, Shahiri P, Hartmann A, Barr M, Parrish M. Racial disparities in urine drug testing on labor and delivery. In: SMFM 41st Annual meeting pregnancy meeting, vol 224; 2021. p. S709.","DOI":"10.1016\/j.ajog.2020.12.1175"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00572-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:38:45Z","timestamp":1638279525000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00572-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We received University of Pennsylvania IRB approval prior to any study activities. All participants provided verbal informed consent, as specified by the IRB, before interviews took place.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was included in the informed consent completed prior to each interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}